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Summary
The maternal Tdap (tetanus, diphtheria and acellular pertussis) vaccination 
programme in the United Kingdom has successfully reduced cases of per-
tussis in young infants. In addition to prevention of pertussis cases, it is 
also important to investigate the persistence of maternal antibodies during 
infancy and the possible interference of maternal antibodies with infant 
responses to vaccines. We recruited mother–infant pairs from vaccinated 
and unvaccinated pregnancies and measured concentrations of immuno-
globulin (Ig)G against pertussis toxin (PTx), filamentous haemagglutinin 
(FHA), pertactin (Prn), diphtheria toxin (DTx), tetanus toxoid (TTx) Hae-
mophilus influenzae type b (Hib) and Streptococcus pneumoniae in mothers 
and infants at birth, and in infants at 7 weeks and at 5 months. Thirty-one 
mother–infant pairs were tested. Tdap-vaccinated women had significantly 
higher antibody against Tdap antigens, compared to unvaccinated women 
(DTx, P   =  0·01; PTx, FHA, Prn and TTx, P   <  0·001). All antibodies were 
actively transferred to the infants (transfer ratio  > 1) with higher transfer 
of DTx (P   =  0·04) and TTx (P   =  0·02) antibody in Tdap-vaccinated preg-
nancies compared to unvaccinated pregnancies. Infants from Tdap-vacci-
nated pregnancies had significantly elevated antibodies to all antigens at 
birth (P  < 0.001) and at 7 weeks (FHA, Prn, TTx, P  < 0·001; DTx, P  = 0.01; 
PTx, P   =  0·004) compared to infants from unvaccinated pregnancies. In-
fants from Tdap-vaccinated and -unvaccinated pregnancies had comparable 
antibody concentrations following primary pertussis immunization (PTx, 
P   =  0·77; FHA, P   =  0·58; Prn, P   =  0·60; DTx, P   =  0·09; TTx, P   =  0·88). 
These results support maternal immunization as a method of protecting 
vulnerable infants during their first weeks of life.
Keywords: antibodies, human, reproductive immunology, vaccination
Introduction
Pertussis is a highly contagious infection of the upper 
respiratory tract caused by the bacterium Bordetella pertussis 
[1]. Although pertussis affects all age groups, complications 
and mortality from infection are highest in infants too 
young to be fully immunized. The resurgence of pertussis 
Clinical and Experimental Immunology OrIgInal artIClE doi: 10.1111/cei.13275
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and 
reproduction in any medium, provided the original work is properly cited.
T. F. Rice et al.
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 00: 00–00
2
in vaccinated populations has caused many infant deaths, 
resulting in a major worldwide public health concern [2]. 
Following 14 infant deaths in the United Kingdom in 2012, 
a nationwide pertussis vaccination programme for pregnant 
women was introduced [3]. The rationale of maternal vac-
cination is to boost the observed low pertussis antibody 
levels in the pregnant population [4], thereby increasing 
levels of antibodies transferred to the fetus in utero . The 
programme in the United Kingdom is safe [5] and highly 
effective [6], with the highest proportional reduction in 
cases and hospital admissions in infants less than 3 months 
of age [7]. Maternal pertussis vaccination has been intro-
duced by the United States, Australia, South American 
and other European countries [8–10].
Following acellular pertussis vaccination during pregnancy, 
antibody concentrations in cord blood to vaccine antigens, 
including pertussis toxin (PTx), filamentous haemagglutinin 
(FHA) and pertactin (Prn), are increased in the infant, and 
to concentrations greater than or equal to those in the mother 
[11], due presumably to active transport of antibodies across 
the placenta [12]. Associations between high maternal anti-
body levels in the infant and subsequent impaired vaccine 
responses have been observed for influenza and measles 
[13,14], and recent studies have suggested that maternal 
pertussis vaccination may be associated with blunted infant 
responses to primary immunization [15–18]. Since the intro-
duction of the programme, no UK study has reported vaccine 
responses in mother–infant pairs from vaccinated pregnancies, 
compared to unvaccinated controls collected during the same 
time-period. Our study thus aimed to determine the impact 
of maternal pertussis vaccination on infant antibody responses 
to primary immunization with acellular pertussis, 
Haemophilus pneumonia type b (Hib) and Streptococcus 
pneumonia  conjugate polysaccharide vaccines.
Materials and methods
Study subjects
Women with singleton, uncomplicated term pregnancies 
booked for maternity care at Imperial College Healthcare 
NHS Trust were recruited antenatally. Exclusion criteria 
included maternal autoimmune disease, hypertension, 
diabetes and pregnancy pathologies. Randomization into 
vaccinated and unvaccinated groups was not possible for 
ethical reasons, as the maternal pertussis vaccination pro-
gramme was in place at the start of the study. The recruits 
gave birth between May 2014 and September 2016 inclu-
sive. The study was approved by Research Ethics Committee 
(13/LO/1712) and written informed consent was obtained.
Serum collection
Maternal serum was routinely collected at time of book-
ing for antenatal care, from the cord immediately at birth 
and from women postnatally within 72  h of delivery. 
Serum was collected from infants at 7  weeks (1 week 
prior to commencing primary immunizations) and 
5  months of age (1  month after completion of primary 
immunizations). Maternal blood collected at the time of 
booking for antenatal care was taken into Vacutainer® 
plastic SSTTM II Advance tubes (Becton Dickinson, 
Wokingham, UK) and stored samples were obtained fol-
lowing patient consent. All other samples were taken into 
Z Serum Sep Clot Activator tubes (Greiner Bio-One, 
Stonehouse, UK) and processed by the study team. Samples 
were left for a minimum of 30  min prior to centrifuga-
tion at 1900 g for 10  min. Maternal and cord blood were 
processed within 48 h of collection and infant blood within 
1 h of collection. All serum aliquots were stored at –80°C 
prior to further analysis.
Vaccines
In line with UK vaccine policy, vaccinated women received 
tetanus, diphtheria and pertussis-containing vaccines 
(Tdap); Repevax® (Sanofi Pasteur, Lyon, France; prior to 
July 2014) or Boostrix-IPV® (GlaxoSmithKline, Wavre, 
Belgium; after July 2014). As per routine vaccination 
schedules in the United Kingdom, infants received three 
doses of tetanus, diphtheria and pertussis-containing vac-
cine at 8, 12 and 16  weeks; DtaP5-IPV-Hib (Pediacel®; 
Sanofi Pasteur) or DtaP3-IPV-Hib (Infanrix-IPV-Hib®; 
GlaxoSmithKline). All infants received two doses of 
13-valent conjugate pneumococcal polysaccharide vaccine, 
Prevenar13® (Pfizer, Puurs, Belgium) at 8 and 16  weeks.
Antibody measurement by multiplex immunoassay
A multiplex immunoassay (MIA) was employed to measure 
antibody concentrations against pertussis, diphtheria, teta-
nus, pneumococcal and Hib vaccine antigens at the Centre 
for Infectious Disease Control, National Institute of Public 
Health and the Environment (RIVM), the Netherlands. 
This assay utilizes antigen-conjugated microspheres to 
quantify immunoglobulin (Ig)G antibodies using Luminex 
xMAP technology. Three separate assays were performed 
as previously described to measure antibodies against: (1) 
protein antigens PT, FHA, Prn, DT and TT [19], (2) 
pneumococcal polysaccharide antigens 1, 4, 5, 6B, 7F, 
9V, 14, 18C, 19F and 23F [20] and (3) the Hib polysac-
charide antigen [21]. In brief, standard, control and serum 
samples were mixed with microspheres conjugated to 
vaccine antigen proteins, and incubated for 30–45 min. 
R-Phycoerythrin-conjugated goat anti-human IgG (Jackson 
ImmunoResearch Laboratories Inc., Westgrove, PA, USA) 
was added to detect bound antibodies. Samples were pro-
cessed using a Bio-Plex 200, and results analysed with 
Bio-Plex Manager software version 6.1 (Bio-Rad 
Laboratories, Hercules, CA, USA).
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Statistical analysis
The primary end-points of the study were the determina-
tion of antibody levels to pertussis and pneumococcal 
vaccine antigens at the five study time-points, stratified 
by immunization status in pregnancy. Based on previous 
antibody studies in pregnant women at a single time-point 
and assuming 95% protection in vaccinated women and 
normal distribution of concentrations between the two 
groups of women, a sample size of 23 per group would 
theoretically be sufficient to show a significant difference 
between vaccinated and unvaccinated women with a power 
of 90%, using a two-sided test with a significance level 
of  <  0·05.
Results below the limit of detection were assigned 
the lower limit of quantification: 1  IU/ml for PT, FHA 
and Prn; 0·001  IU/ml for DT and TT; and 0·01  µg/ml 
for Hib and all pneumococcal polysaccharide antigens. 
Appropriate parametric/non-parametric tests were used 
following testing for Gaussian distribution using the 
D’Agostino–Pearson omnibus normality test. Distribution 
of measures and effects of potential outlying values were 
examined [22]. Outcomes symmetrized by log-transfor-
mation were analysed using mixed-effects linear regres-
sion with a random intercept at the participant level 
(mixed command in Stata); χ2 or t -tests identified baseline 
characteristics for which the treatment group was not 
balanced. We estimated the effect of vaccination on 
antibody concentrations via interactions between the 
treatment group and time, adjusting variables for groups 
which were not balanced at baseline or follow-up. 
Marginalization was used to present group differences 
of each time-point (by use of the contrast and margins 
post-estimation commands in stata). Results were 
adjusted for gestation at delivery. Comparisons of lon-
gitudinal antibody concentrations and the effect of ges-
tation at time of maternal vaccination were performed 
using stata version 15.
The proportion of infant samples with DTx and TTx 
antibodies ≥0·1  IU/ml [23], and with PTx, FHA and Prn 
antibodies ≥20  IU/ml [24] were calculated. Comparisons 
of transfer ratios and antibody half-life between vaccinated 
and unvaccinated groups were made using the Mann–
Whitney U -test in GraphPad Prism version 7. P -values 
less than 0·05 were considered significant.
Results
Study population demographics
We included a total of 150 serum samples, collected from 
31 mother–infant pairs, with 16 obtained from Tdap-
vaccinated pregnancies and 15 from unvaccinated preg-
nancies. At the 5-month time-point, five samples could 
not be obtained in the unvaccinated group, as mothers 
withdrew consent for further sampling. Detailed clinical 
data and a study flow diagram are shown in Supporting 
information, Table S1 and Fig. S1, respectively. There were 
no significant demographic nor clinical differences between 
vaccinated and unvaccinated mother–infant pairs apart 
from higher parity in unvaccinated mothers, which was 
corrected for in the analyses.
Robust maternal antibody responses to Tdap booster 
vaccination in pregnancy
At the time of delivery, vaccinated women had significantly 
higher antibodies against all Tdap vaccine antigens 
(PTx  3·45  IU/ml; FHA  4·55  IU/ml; Prn  5·86  IU/ml; 
DTx  0·60  IU/ml; TTx  1·59  IU/ml) than unvaccinated 
mothers (PTx  2·01  IU/ml, P   <  0·001; FHA  2·31  IU/ml, 
P   <  0·001; Prn  1·66  IU/ml, P   <  0·001; DTx  0·19  IU/ml, 
P   =  0·01; TTx  0·63  IU/ml, P   <  0·001) (Fig. 1; for raw 
data see Supporting information, Table S2). Women in 
the Tdap-vaccinated group had higher TTx antibodies at 
baseline, prior to vaccination (1·06  IU/ml) than those 
who were not vaccinated (0·63  IU/ml; P   =  0·02), which 
was controlled for in the analysis.
Maternal vaccination is associated with elevated 
transplacental anti-DTx and -TTx antibody transfer
Ratios between cord and maternal antibody levels at the 
time of delivery were calculated to measure transplacental 
antibody transfer. There was positive transport of antibod-
ies to the infant for all Tdap vaccine antigens, independent 
of vaccination status (Table 1). The transplacental transfer 
of DTx (2·10) and TTx (2·07) was significantly higher in 
vaccinated groups compared to unvaccinated groups 
(DTx  1·64, P   =  0·04; TTx  1·58, P   =  0·02).
Elevated vaccine-specific antibodies in infants in the 
first 7 weeks of life after vaccination during pregnancy
Infant blood was collected at birth and 7  weeks, prior 
to commencement of primary immunization. Infants 
born to vaccinated mothers had significantly higher 
antibodies against all Tdap vaccine antigens at birth 
(PTx  4·15  IU/ml; FHA  5·27  IU/ml; Prn  6·60  IU/ml; 
DTx  0·90  IU/ml; TTx  2·15  IU/ml) than infants from 
unvaccinated mothers (PTx  2·50  IU/ml; FHA  3·03  IU/
ml; Prn  2·24  IU/ml; DTx  0·26  IU/ml; TTx  0·80  IU/ml; 
all P   <  0·001) (Fig. 1).
At 7 weeks (Fig. 1), infants from vaccinated pregnan-
cies had significantly elevated anti-PTx (3·15 IU/ml), FHA 
(4·27  IU/ml), Prn (5·77  IU/ml), DTx (0·38  IU/ml) and 
TTx (1·28  IU/ml) antibodies compared to infants from 
unvaccinated pregnancies (PTx  1·88  IU/ml, P   =  0·004; 
FHA  1·71  IU/ml, P   <  0·001; Prn    1·27  IU/ml, P   <  0·001; 
DTx  0·10  IU/ml, P   =  0·01; TTx  0·31  IU/ml, P   <  0·001). 
T. F. Rice et al.
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Maternal vaccination had no effect on the half-life of any 
of the Tdap antibodies (Table 2).
The percentage of infants reaching protective levels of 
DTx and TTx antibodies (≥0·1  IU/ml) was calculated 
based on defined thresholds. Based on other published 
literature, the percentage of infants reaching an arbitrary 
threshold of ≥20  IU/ml was reported for the pertussis 
antigens, as there is no known correlate of protection. 
At birth and 7  weeks, a significantly higher proportion 
of infants from Tdap-vaccinated pregnancies had PTx, 
FHA and Prn antibodies ≥20  IU/ml and were seropro-
tected for DTx (≥0·1  IU/ml), compared to unvaccinated 
pregnancies (Fig. 1). There was no difference in the pro-
portion of infants that were seroprotected for TTx antibody 
from vaccinated and unvaccinated pregnancies at any 
time-point.
Impact of maternal Tdap vaccination on the infant 
response to primary pertussis vaccination
To determine the impact of maternal Tdap vaccination 
on infant responses to pertussis vaccination, blood was 
collected 1  month after completing their primary course 
of DTaP-IPV-Hib vaccine (8, 12 and 16  weeks). No 
differences were observed in antibody concentrations, 
or the percentage of infants reaching defined thresholds 
to any DTaP vaccine antigens, between infants from 
vaccinated and unvaccinated pregnancies (Fig. 1). There 
were no correlations between the concentrations of anti-
body at birth and in infants post-primary immunization, 
either in vaccinated or unvaccinated groups (data not 
shown).
Impact of maternal Tdap vaccination on 
pneumococcal and Hib antibody levels in infants
In addition to paediatric DTaP vaccine, potential effects 
of maternal Tdap vaccination on other vaccines in the 
primary vaccination schedule were investigated for Hib 
and pneumococcal polysaccharide serotypes (ST) 1, 4, 5, 
6B, 7F, 9V, 14, 18C, 19F and 23F. Pneumococcal and 
Hib antibody concentrations in 7-week-old infants did 
not differ between infants from vaccinated and unvac-
cinated pregnancies (Fig. 2). One month after primary 
PCV13 vaccinations (8 and 16 weeks), infants from unvac-
cinated pregnancies had significantly higher antibodies 
against ST7F (2·28  IU/ml, P   =  0·002), whereas ST14 was 
increased in infants from vaccinated pregnancies (1·34, 
P  = 0·004, P  = 0·044) (Fig. 2; for raw data, see Supporting 
information, Table S2). There were no significant differ-
ences in antibody to all other antigens between infants 
born to Tdap vaccinated and unvaccinated mothers, includ-
ing Hib.
Table 1. Active transfer of tetanus, diphtheria and acellular pertussis 
(Tdap) vaccine-specific antibodies from mother to infant. Mean fetal/
maternal antibody ratios and 95% confidence intervals (CI) for IgG 
against Tdap antigens PTx, FHA, Prn, DTx and TTx
Fetal/maternal IgG ratios (CI)
Vaccine Antigen Unvaccinated Vaccinated P-value
PTx 2·28 (1·16–3·41) 2·16 (1·80–2·53) 0·41
FHA 2·23 (1·53–2·93) 2·15 (1·79–2·51) 0·62
Prn 2·33 (1·07–3·60) 2·14 (1·79–2·69) 0·08
DTx 1·64 (1·42–1·87) 2·10 (1·76–2·46) 0·04
TTx 1·58 (1·35–1·81) 2·07 (1·76–2·39) 0·03
Ig = immunoglobulin; PTx = pertussis toxin; FHA = filamentous hae-
magglutinin; Prn = pertactin; DTx = diphtheria toxin; TTx = tetanus 
toxoid.
Table 2. Half-life of tetanus, diphtheria and acellular pertussis (Tdap)-
specific maternal antibody between birth and 7 weeks. Mean half-life in 
days and 95% confidence intervals (CI) for maternal IgG against Tdap 
antigens PTx, FHA, Prn, DTx and TTx
IgG half-life in infants, in days (CI)
Vaccine Antigen Unvaccinated Vaccinated P-value
PTx 27·2 (20·0–42·3) 28·9 (26·9–31·3) 0·65
FHA 25·0 (19·5–34·7) 29·7 (27·7–32·1) 0·72
Prn 26·1 (18·5–44·4) 28·1 (25·4–31·3) 0·47
DTx 21·8 (18·2–27·2) 26·1 (24·5–27·9) 0·16
TTx 26·6 (19·3–42·6) 29·5 (26·8–32·8) 0·62
Ig = immunoglobulin; PTx = pertussis toxin; FHA = filamentous hae-
magglutinin; Prn = pertactin; DTx = diphtheria toxin; TTx = tetanus 
toxoid.
Fig. 1. Anti-tetanus, diphtheria and acellular pertussis (Tdap) antibody concentrations in mothers and their infants from Tdap-vaccinated and 
-unvaccinated pregnancies (a–e). The proportion of infants from Tdap-vaccinated and -unvaccinated pregnancies reaching antibody thresholds (f–j). 
(a–e) Anti-Tdap immunoglobulin (Ig)G were quantified in mother–infant pairs from vaccinated (white circle) and unvaccinated (black circle) 
pregnancies. Data were log-transformed, and a random-effects model applied. Mean and 95% confidence intervals are shown. The vaccinated group 
had significantly elevated antibodies to (a) PTx, (b) FHA, (c) Prn, (d) Dtx and (e) TTx vaccine antigens in mothers at birth, in cord blood and in the 
infant prevaccination (pre-vac; 7 weeks of age). Post-infant vaccination (post-vac; 5 months of age), there were no significant differences in antibody 
to any of the vaccine antigens between vaccinated and unvaccinated groups (*P  < 0·05; ***P  < 0·001; ****P  < 0·0001; unvaccinated n  = 15; vaccinated 
n  = 16). (f–j) Cut-offs were set at ≥20 IU/ml for pertussis antigens and ≥0·1 IU/ml for DTx and TTx. The proportion of infants at birth, 7 weeks and 
5 months that reached these cut-offs is represented as a percentage of total samples analysed in vaccinated (solid line) and unvaccinated (dashed line) 
groups. At birth and 7 weeks, the percentage of infants reaching seropositive levels for PTx, FHA, Prn and DTx was significantly higher in the group 
born to Tdap-vaccinated mothers than those born to non-vaccinated mothers. There was no difference for TTx. Post-primary immunization, there 
was no difference between the two groups (**P  < 0·01; ***P  < 0·001; ****P  < 0·0001).
T. F. Rice et al.
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Fig. 2. Longitudinal pneumococcal and Haemophilus influenzae (Hib) antibody concentrations in mothers and their infants from maternal tetanus, 
diphtheria and acellular pertussis (Tdap) vaccinated and unvaccinated pregnancies. Immunoglobulin (Ig)G against pneumococcal serotypes (Ps) and 
Hib were quantified in mother–infant pairs from vaccinated (white circles) and unvaccinated (black circles) pregnancies. Data were log-transformed, 
and a random-effects model applied. Mean and 95% confidence intervals are shown. No differences were observed in antibody to serotypes (a) 1, (b) 
4, (c) 5, (d) 6B, (e) 7F, (f) 9V, (g) 14, (h) 18C, (i) 19F, (j) 23F in mothers during pregnancy and at birth, or in cord blood and the infant prevaccination 
(pre-vac; 7 weeks of age). Post-vaccination (post-vac; 5 months of age), infants from vaccinated pregnancies had elevated serotype 14, whereas infants 
from the unvaccinated group had elevated 7F. (k) Hib antibody did not differ between vaccinated and unvaccinated groups at any study time-points 
(*P  < 0·05; **P  < 0·01; unvaccinated n  = 15; vaccinated n  = 16).
Antibody responses to Bordetella pertussis
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Discussion
Although the maternal pertussis vaccination programme 
in the United Kingdom has successfully reduced cases of 
pertussis in young infants [6,7], it is important to deter-
mine whether increased maternal pertussis antibody in 
infants is associated with blunted responses to paediatric 
vaccines. Given that vaccine interference by maternal 
antibodies has been shown for vaccines such as measles, 
we determined anti-pertussis, diphtheria, tetanus, Hib and 
pneumococcal antibody levels in a prospective cohort of 
maternally vaccinated and unvaccinated mother–infant 
pairs. In our small study population, we found that mater-
nal Tdap vaccination results in robust antibody concen-
trations in mothers and, importantly, in their infants 
during the critical first weeks of life. With this sample 
size, we did not detect any significant impact of maternal 
Tdap vaccination on infant responses to primary pertussis 
vaccination.
We observed active transplacental transfer of mater-
nal antibodies in Tdap-vaccinated and -unvaccinated 
groups, as reported by previous studies [15,16,18,25]. 
High levels of maternal antibodies have been linked 
to reduced transfer ratios, due potentially to satura-
tion of the neonatal Fc receptor (FcRn) for IgG in 
the placenta [26]. We observed no such association, 
and conversely, transfer of DTx and TTx antibodies 
were significantly higher in Tdap-vaccinated pregnan-
cies compared to unvaccinated pregnancies, suggesting 
that the FcRn is not saturated by the IgG levels induced 
by maternal vaccination. Maternal antibodies in the 
infant wane with time, with varying rates reported 
[15,27]. We report a half-life of between 25 and 
29·7  days, depending on the antigen. Importantly, the 
half-life of the antibody from vaccinated pregnancies 
is the same as that from unvaccinated pregnancies, 
meaning that antibodies induced by vaccination in 
pregnancy are just as long-lasting as antibodies that 
are present in the mother from previous exposure/
vaccination.
Between birth and 7  weeks, infants from vaccinated 
pregnancies had significantly higher concentrations of 
antibodies against all acellular pertussis antigens. We used 
published cut-offs for tetanus and diphtheria to define 
protective antibody concentrations [23]. No correlate of 
protection has been defined for pertussis [1]; however, 
high antibody levels are important [28,29]. Several papers 
have used arbitrary thresholds when analysing pertussis 
antibody levels [24,30,31], and thus for our analysis we 
utilised the commonly used arbitrary threshold of ≥20 IU/
ml for PTx, FHA and Prn antibody concentrations. A 
significantly higher percentage of infants from vaccinated 
pregnancies reached these antibody levels for tetanus and 
diphtheria, and the arbitrarily defined threshold for 
pertussis antibody in the first 7  weeks of life, compared 
to infants born from unvaccinated mothers.
Following primary immunization, no differences were 
observed in concentrations of pertussis antibodies 
between infants from vaccinated and unvaccinated preg-
nancies. Although it appears that there is a downward 
trend in infant FHA, Prn, DTx and TTx antibody levels 
in the vaccinated group between the 7-week and 5-month 
time-points, it is important to note that the 7-week 
time-point is essentially a measurement of maternal 
antibody in infants. As shown by our data, we would 
expect higher levels of maternal antibodies in infants 
whose mothers were vaccinated during pregnancy. Unlike 
in the mothers, it is not possible to compare the pre- 
and post-vaccination antibody levels in infants to measure 
their response to pertussis vaccination because of the 
presence of maternal antibody at the 7-week time- 
point.
In contrast to our findings, a previous larger study 
in Belgium found that infants from vaccinated pregnan-
cies had lower concentrations of PTx and DTx antibodies 
following primary immunization, compared to infants 
from unvaccinated mothers [15]. Lower DTx and Prn 
antibodies have also been observed in infants from 
Tdap-vaccinated mothers in Vietnam, compared to a 
control group whose mothers received a tetanus vaccine 
during pregnancy [16]. The difference between our study 
and previous studies could be due simply to our limited 
sample size but also due to women’s vaccination his-
tories, maternal/paediatric vaccine formulations and, in 
the case of the Vietnamese study, different epidemio-
logical backgrounds, including natural exposure to B. 
pertussis . In the only other study in the United Kingdom, 
infants from vaccinated pregnancies have previously been 
shown to have lower PTx, FHA and fimbriae 2/3 anti-
bodies after DTaP vaccination, compared to infants from 
unvaccinated pregnancies [17]. However, the unvacci-
nated control group in this study was a historical set 
of infant samples collected 10  months prior to the 
introduction of the maternal vaccination programme in 
response to the pertussis outbreak. Thus, these groups 
could have different confounders, including pertussis 
exposure, particularly as pertussis prevalence is seasonal 
[1]. In contrast, our study collected samples from vac-
cinated and unvaccinated pregnancies during the same 
time-period.
Pertussis vaccination during pregnancy has been associ-
ated with reduced infant responses to other vaccines, such 
as pneumococcal vaccination [17,32]. We did not observe 
any differences in the response to Hib vaccination. We 
also saw very few differences in the concentration of 
serotype-specific anti-pneumococcal antibody between 
groups; 5-month-old infants from unvaccinated 
T. F. Rice et al.
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pregnancies had elevated ST7F antibodies compared to 
vaccinated pregnancies and, conversely, vaccinated infants 
had elevated ST14. However, if we perform Bonferroni 
correction for the 10  serotypes that were measured, the 
cut-off for significance is P  < 0·005, which the ST7F and 
ST14 differences do not reach. In contrast to our find-
ings, Ladhani et al . [17] and Maertens et al . [32] observed 
blunting of multiple pneumococcal serotypes in infants 
from Tdap-vaccinated pregnancies. The blunting of pneu-
mococcal responses was largely removed following a 
booster vaccination at 12  months of age [32]. The reason 
for the differences between our findings and these studies 
is not clear, but could be due to our small sample size; 
continued monitoring of the impact of pertussis vaccina-
tion during pregnancy on infant responses to other vac-
cines is required.
Antibodies produced following acellular vaccination 
wane rapidly [33]. The dynamics of the maternal anti-
pertussis antibody response to vaccination and the effi-
ciency of transplacental antibody transfer rates across 
gestation need to be considered. In 2016, health authorities 
in the United Kingdom recommended that maternal per-
tussis vaccination should be provided earlier in pregnancy, 
between 16 and 32  weeks of gestation, partly based on 
evidence that vaccination in the early second trimester 
(13–25  weeks) resulted in higher cord blood antibody 
levels than third-trimester vaccination (≥26  weeks) [34]. 
Earlier vaccination is now also recommended in Ireland, 
Argentina and Mexico, among others. The extended vac-
cination window also enables women to be immunized 
at the time of the 20-week fetal anomaly scan, potentially 
increasing the opportunity to administer the vaccine. An 
additional consideration is preterm birth, which affects 
8·6% of births in developed countries [35]. Earlier vac-
cination could also protect these preterm infants [36]. 
We were not able to investigate how the timing of per-
tussis vaccination impacts on antibody levels. Future studies 
should analyse the impact of timing of pertussis vaccina-
tion during pregnancy and monitor antibody levels between 
pregnancies to determine whether pertussis vaccination 
is required with each pregnancy, regardless of the time 
between pregnancies.
The main limitation of the data presented here is the 
small number of women and infants with paired samples 
included: only a small proportion of women agreed to come 
back for infant follow-up in observational cohort studies 
with little tangible benefit for healthy babies. Therefore, our 
inability to detect potential blunting in vaccine responses 
in infants born to vaccinated mothers could simply be due 
to lack of power. We estimated 95% confidence intervals 
of the effect sizes using bootstrapping, to determine the 
degree of uncertainty around our estimates. Taking the 
example of PTx, although we had a very small effect size 
of –0·1, the bootstrapped confidence interval ranged from 
–0·78 to 0·66, prohibiting our ability to definitively conclude 
that there is no difference between the vaccinated and 
unvaccinated groups. We believe that our study provides 
useful data for power calculations of future longitudinal 
mother–infant cohort studies, including the measurement 
of antibodies against a range of different vaccines (Tdap/
DTaP, pneuomoccocal and Hib), antibody half-life, vaccine 
interference and the impact of gestation at vaccination.
The UK vaccination schedule at the time of the study 
meant that both women (Repevax® or Boostrix-IPV®) and 
infants (Pediacel® or Infanrix-IPV-Hib®) received one of 
two vaccines with different antigenic composition. The 
multiplex assay did not measure FIM antibody contained 
in both Repevax® and Pediacel®. Feunou et al. [37] dem-
onstrated in mice that there is the potential for greater 
interference of maternal antibody when mother–infant 
pairs receive vaccines from the same manufacturer. We 
were unable to carry out this type of analysis, given that 
the majority of women in our study (14 of 16) were 
vaccinated with Boostrix-IPV®, which does not contain 
FIM antigen. There is a clinical trial in the United Kingdom 
to compare antibody levels following maternal vaccination 
with different Tdap vaccines (ClinicalTrials.gov identifier 
NCT02145624) that could shed further light on these 
observations from the mouse model.
Conclusions
In the United Kingdom, maternal pertussis vaccination 
during pregnancy protects infants during the critical first 
weeks of life before commencement of paediatric vaccina-
tion, confirming underlying principles for protection of 
vulnerable newborns against vaccine-preventable infections 
via maternal immunization. In this small study, we found 
that maternal Tdap vaccination results in robust antibody 
concentrations in infants during their critical first weeks 
of life, before they receive primary immunization. Future 
studies should include investigation of the optimal gesta-
tion at which to vaccinate pregnant women to maximize 
high-vaccine coverage and protection of infants.
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